Pharma: Other News To Note
• Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA has accepted for standard review its new drug application for its investigational anti-thrombotic medicine, vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter